Product information and disease descriptionPlace of product in therapyApproaches to treatment
Other product development or post-marketing obligations required by the FDA
3 evidence topics · 4 sources
FDA alignment on the 90 mg dose for OPERA-01 Part 2 and OPERA-02
Randomized dose selection in OPERA-01 Part 1
“The Independent Data Monitoring Committee recommended a 90-mg palazestrant QD dose based on the available safety, efficacy, patient-reported outcomes, and pharmacokinetic data from participants treated with palazestrant 90 mg and 120 mg in Part 1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Safety, efficacy, and PRO outcomes at the non-selected dose” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
REMS and post-approval requirements described by the company
Post-marketing requirements or commitments
Not applicable.